Suppression of glut1 and glucose metabolism by decreased Akt/mTORC1 signaling drives T cell impairment in B cell leukemia

Journal of Immunology

Volumn 197, Issue 6, 2016, Pages 2532-2540

  Siska, Peter J ^a,b,c   Van Der Windt, Gerritje J W ^d   Kishton, Rigel J ^a   Cohen, Sivan ^a   Eisner, William ^a   MacIver, Nancie J ^a   Kater, Arnon P ^d,e   Weinberg, J Brice ^a,f   Rathmell, Jeffrey C ^a,b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Lymphoma and Myeloma Center Amsterdam (LYMMCARE)   (Netherlands)

^f DURHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CD200 RECEPTOR; CD28 ANTIGEN; CD69 ANTIGEN; CD71 ANTIGEN; CHECKPOINT KINASE 2; GAMMA INTERFERON; GLUCOSE TRANSPORTER 1; HEXOKINASE; INTERLEUKIN 2 RECEPTOR ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE B; GLUCOSE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE;

AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CELL SIZE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME REPRESSION; FLOW CYTOMETRY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; METABOLIC DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STROMA CELL; T CELL LYMPHOBLASTIC LEUKEMIA CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CARBOHYDRATE METABOLISM; CHRONIC LYMPHATIC LEUKEMIA; CYTOLOGY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; SPLEEN; TUMOR CELL LINE;

ANIMALS; CARBOHYDRATE METABOLISM; CELL LINE, TUMOR; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; GLYCOLYSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE ACTIVATION; MICE; MULTIPROTEIN COMPLEXES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPLEEN; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84988945642     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1502464     Document Type: Article

References (53)

1. O'Connor, D., J. Bate, R. Wade, R. Clack, S. Dhir, R. Hough, A. Vora, N. Goulden, and S. Samarasinghe. 2014. Infection-related mortality in children with acute lymphoblastic leukemia: an analysis of infectious deaths on UKALL2003. Blood 124: 1056-1061.
2. Melchardt, T., L. Weiss, R. Greil, and A. Egle. 2013. Viral infections and their management in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 54: 1602-1613.
3. Thijssen, R., J. Ter Burg, G. G. van Bochove, M. F. de Rooij, A. Kuil, M. H. Jansen, T. W. Kuijpers, J. W. Baars, A. Virone-Oddos, M. Spaargaren, et al. 2016. The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia 30: 337-345.
4. Görgün, G., T. A. Holderried, D. Zahrieh, D. Neuberg, and J. G. Gribben. 2005. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J. Clin. Invest. 115: 1797-1805.
5. Riches, J. C., J. K. Davies, F. McClanahan, R. Fatah, S. Iqbal, S. Agrawal, A. G. Ramsay, and J. G. Gribben. 2013. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 121: 1612-1621.
6. Christopoulos, P., D. Pfeifer, K. Bartholomé, M. Follo, J. Timmer, P. Fisch, and H. Veelken. 2011. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 117: 3836-3846.
7. Yotnda, P., P. Mintz, K. Grigoriadou, F. Lemonnier, E. Vilmer, and P. Langlade-Demoyen. 1999. Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells. Exp. Hematol. 27: 1375-1383.
8. Brusa, D., S. Serra, M. Coscia, D. Rossi, G. D'Arena, L. Laurenti, O. Jaksic, G. Fedele, G. Inghirami, G. Gaidano, et al. 2013. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia. Haematologica 98: 953-963.
9. Nunes, C., R. Wong, M. Mason, C. Fegan, S. Man, and C. Pepper. 2012. Expansion of a CD8+PD-1+ replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. [Published erratum appears in 2012 Clin. Cancer Res. 18: 3714.] Clin. Cancer Res. 18: 678-687.
10. Wherry, E. J., S. J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. [Published erratum appears in 2007 Immunity 27: 824.] Immunity 27: 670-684.
11. Bucks, C. M., J. A. Norton, A. C. Boesteanu, Y. M. Mueller, and P. D. Katsikis. 2009. Chronic antigen stimulation alone is sufficient to drive CD8+ T cell exhaustion. J. Immunol. 182: 6697-6708.
12. Wherry, E. J. 2011. T cell exhaustion. Nat. Immunol. 12: 492-499.
13. Schietinger, A., and P. D. Greenberg. 2014. Tolerance and exhaustion: defining mechanisms of T cell dysfunction. Trends Immunol. 35: 51-60.
14. Rossmann, E. D., M. Jeddi-Tehrani, A. Osterborg, and H. Mellstedt. 2003. T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL): an increased abnormal expression by advancing stage. Leukemia 17: 2252-2254.
15. Van den Hove, L. E., P. Vandenberghe, S.W. Van Gool, J. L. Ceuppens, H. Demuynck, G. E. Verhoef, and M. A. Boogaerts. 1998. Peripheral blood lymphocyte subset shifts in patients with untreated hematological tumors: evidence for systemic activation of the T cell compartment. Leuk. Res. 22: 175-184.
16. Yang, Z. Z., D. M. Grote, B. Xiu, S. C. Ziesmer, T. L. Price-Troska, L. S. Hodge, D. M. Yates, A. J. Novak, and S. M. Ansell. 2014. TGF-b upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia 28: 1872-1884.
17. McClanahan, F., B. Hanna, S. Miller, A. J. Clear, P. Lichter, J. G. Gribben, and M. Seiffert. 2015. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 126: 203-211.
18. MacIver, N. J., R. D. Michalek, and J. C. Rathmell. 2013. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31: 259-283.
19. Wieman, H. L., J. A. Wofford, and J. C. Rathmell. 2007. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol. Biol. Cell 18: 1437-1446.
20. Jacobs, S. R., C. E. Herman, N. J. Maciver, J. A. Wofford, H. L. Wieman, J. J. Hammen, and J. C. Rathmell. 2008. Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. J. Immunol. 180: 4476-4486.
21. Pollizzi, K. N., and J. D. Powell. 2015. Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 36: 13-20.
22. Macintyre, A. N., V. A. Gerriets, A. G. Nichols, R. D. Michalek, M. C. Rudolph, D. Deoliveira, S. M. Anderson, E. D. Abel, B. J. Chen, L. P. Hale, and J. C. Rathmell. 2014. The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function. Cell Metab. 20: 61-72.
23. Michalek, R. D., V. A. Gerriets, S. R. Jacobs, A. N. Macintyre, N. J. MacIver, E. F. Mason, S. A. Sullivan, A. G. Nichols, and J. C. Rathmell. 2011. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. J. Immunol. 186: 3299-3303.
24. Chang, C. H., J. D. Curtis, L. B. Maggi, Jr., B. Faubert, A. V. Villarino, D. O'Sullivan, S. C. Huang, G. J. van der Windt, J. Blagih, J. Qiu, et al. 2013. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153: 1239-1251.
25. Zheng, Y., G. M. Delgoffe, C. F. Meyer, W. Chan, and J. D. Powell. 2009. Anergic T cells are metabolically anergic. J. Immunol. 183: 6095-6101.
26. Patsoukis, N., K. Bardhan, P. Chatterjee, D. Sari, B. Liu, L. N. Bell, E. D. Karoly, G. J. Freeman, V. Petkova, P. Seth, et al. 2015. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6: 6692.
27. Parry, R. V., J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein, S. V. Kobayashi, P. S. Linsley, C. B. Thompson, and J. L. Riley. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25: 9543-9553.
28. Rathmell, J. C., R. L. Elstrom, R. M. Cinalli, and C. B. Thompson. 2003. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 33: 2223-2232.
29. Zhao, Y., B. J. Altman, J. L. Coloff, C. E. Herman, S. R. Jacobs, H. L. Wieman, J. A. Wofford, L. N. Dimascio, O. Ilkayeva, A. Kelekar, et al. 2007. Glycogen synthase kinase 3a and 3b mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol. Cell. Biol. 27: 4328-4339.
30. McKearn, J. P., J. McCubrey, and B. Fagg. 1985. Enrichment of hematopoietic precursor cells and cloning of multipotential B-lymphocyte precursors. Proc. Natl. Acad. Sci. USA 82: 7414-7418.
31. Mason, E. F., Y. Zhao, P. Goraksha-Hicks, J. L. Coloff, H. Gannon, S. N. Jones, and J. C. Rathmell. 2010. Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res. 70: 8066-8076.
32. Hallek, M., B. D. Cheson, D. Catovsky, F. Caligaris-Cappio, G. Dighiero, H. Döhner, P. Hillmen, M. J. Keating, E. Montserrat, K. R. Rai, and T. J. Kipps, International Workshop on Chronic Lymphocytic Leukemia. 2008. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111: 5446-5456.
33. Zou, C., Y. Wang, and Z. Shen. 2005. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J. Biochem. Biophys. Methods 64: 207-215.
34. Patsoukis, N., L. Li, D. Sari, V. Petkova, and V. A. Boussiotis. 2013. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell. Biol. 33: 3091-3098.
35. Yamazaki, T., H. Akiba, H. Iwai, H. Matsuda, M. Aoki, Y. Tanno, T. Shin, H. Tsuchiya, D. M. Pardoll, K. Okumura, et al. 2002. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol. 169: 5538-5545.
36. Chen, X., D. Fosco, D. E. Kline, L. Meng, S. Nishi, P. A. Savage, and J. Kline. 2014. PD-1 regulates extrathymic regulatory T-cell differentiation. Eur. J. Immunol. 44: 2603-2616.
37. Francisco, L. M., V. H. Salinas, K. E. Brown, V. K. Vanguri, G. J. Freeman, V. K. Kuchroo, and A. H. Sharpe. 2009. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206: 3015-3029.
38. Chen, X., S. Liu, L. Wang, W. Zhang, Y. Ji, and X. Ma. 2008. Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia. Cancer Biol. Ther. 7: 622-627.
39. Düvel, K., J. L. Yecies, S. Menon, P. Raman, A. I. Lipovsky, A. L. Souza, E. Triantafellow, Q.Ma, R. Gorski, S. Cleaver, et al. 2010. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39: 171-183.
40. Wang, R., C. P. Dillon, L. Z. Shi, S. Milasta, R. Carter, D. Finkelstein, L. L. McCormick, P. Fitzgerald, H. Chi, J. Munger, and D. R. Green. 2011. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35: 871-882.
41. Crawford, A., J. M. Angelosanto, C. Kao, T. A. Doering, P. M. Odorizzi, B. E. Barnett, and E. J. Wherry. 2014. Molecular and transcriptional basis of CD4+ T cell dysfunction during chronic infection. Immunity 40: 289-302.
42. Doedens, A. L., A. T. Phan, M. H. Stradner, J. K. Fujimoto, J. V. Nguyen, E. Yang, R. S. Johnson, and A. W. Goldrath. 2013. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen. Nat. Immunol. 14: 1173-1182.
43. Ho, P. C., J. D. Bihuniak, A. N. Macintyre, M. Staron, X. Liu, R. Amezquita, Y. C. Tsui, G. Cui, G. Micevic, J. C. Perales, et al. 2015. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162: 1217-1228.
44. Chang, C. H., J. Qiu, D. O'Sullivan, M. D. Buck, T. Noguchi, J. D. Curtis, Q. Chen, M. Gindin, M. M. Gubin, G. J. van der Windt, et al. 2015. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162: 1229-1241.
45. Kowalewski, D. J., H. Schuster, L. Backert, C. Berlin, S. Kahn, L. Kanz, H. R. Salih, H. G. Rammensee, S. Stevanovic, and J. S. Stickel. 2015. HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). [Published erratum appears in 2015 Proc. Natl. Acad. Sci. USA 112: E6254-E6256.] Proc. Natl. Acad. Sci. USA 112: E166-E175.
46. Rajasagi, M., S. A. Shukla, E. F. Fritsch, D. B. Keskin, D. DeLuca, E. Carmona, W. Zhang, C. Sougnez, K. Cibulskis, J. Sidney, et al. 2014. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 124: 453-462.
47. Kessler, J. H., and C. J. Melief. 2007. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 21: 1859-1874.
48. Delgoffe, G. M., T. P. Kole, Y. Zheng, P. E. Zarek, K. L. Matthews, B. Xiao, P. F. Worley, S. C. Kozma, and J. D. Powell. 2009. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832-844.
49. Siska, P. J., and J. C. Rathmell. 2015. T cell metabolic fitness in antitumor immunity. Trends Immunol. 36: 257-264.
50. Topalian, S. L., M. Sznol, D. F. McDermott, H. M. Kluger, R. D. Carvajal, W. H. Sharfman, J. R. Brahmer, D. P. Lawrence, M. B. Atkins, J. D. Powderly, et al. 2014. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. 32: 1020-1030.
51. Kater, A. P., and G. J. van der Windt. 2015. PD-L1 blockade: rejuvenating T cells in CLL. Blood 126: 126-128.
52. Pallasch, C. P., S. Ulbrich, R. Brinker, M. Hallek, R. A. Uger, and C. M.Wendtner. 2009. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk. Res. 33: 460-464.
53. Long, A. H.,W. M. Haso, J. F. Shern, K.M.Wanhainen, M. Murgai, M. Ingaramo, J. P. Smith, A. J. Walker, M. E. Kohler, V. R. Venkateshwara, et al. 2015. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21: 581-590.